Allosteric modulation of adenosine A1 and cannabinoid 1 receptor signaling by G-peptides
© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics..
While allosteric modulation of GPCR signaling has gained prominence to address the need for receptor specificity, efforts have mainly focused on allosteric sites adjacent to the orthosteric ligand-binding pocket and lipophilic molecules that target transmembrane helices. In this study, we examined the allosteric influence of native peptides derived from the C-terminus of the Gα subunit (G-peptides) on signaling from two Gi-coupled receptors, adenosine A1 receptor (A1 R) and cannabinoid receptor 1 (CB1 ). We expressed A1 R and CB1 fusions with G-peptides derived from Gαs, Gαi, and Gαq in HEK 293 cells using systematic protein affinity strength modulation (SPASM) and monitored the impact on downstream signaling in the cell compared to a construct lacking G-peptides. We used agonists N6 -Cyclopentyladenosine (CPA) and 5'-N-Ethylcarboxamidoadenosine (NECA) for A1 R and 2-Arachidonoylglycerol (2-AG) and WIN 55,212-2 mesylate (WN) for CB1 . G-peptides derived from Gαi and Gαq enhance agonist-dependent cAMP inhibition, demonstrating their effect as positive allosteric modulators of Gi-coupled signaling. In contrast, both G-peptides suppress agonist-dependent IP1 levels suggesting that they differentially function as negative allosteric modulators of Gq-coupled signaling. Taken together with our previous studies on Gs-coupled receptors, this study provides an extended model for the allosteric effects of G-peptides on GPCR signaling, and highlights their potential as probe molecules to enhance receptor specificity.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
Pharmacology research & perspectives - 8(2020), 6 vom: 06. Dez., Seite e00673 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Touma, Anja M [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 03.09.2021 Date Revised 03.09.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/prp2.673 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316932779 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316932779 | ||
003 | DE-627 | ||
005 | 20231225162144.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/prp2.673 |2 doi | |
028 | 5 | 2 | |a pubmed24n1056.xml |
035 | |a (DE-627)NLM316932779 | ||
035 | |a (NLM)33124765 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Touma, Anja M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Allosteric modulation of adenosine A1 and cannabinoid 1 receptor signaling by G-peptides |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.09.2021 | ||
500 | |a Date Revised 03.09.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. | ||
520 | |a While allosteric modulation of GPCR signaling has gained prominence to address the need for receptor specificity, efforts have mainly focused on allosteric sites adjacent to the orthosteric ligand-binding pocket and lipophilic molecules that target transmembrane helices. In this study, we examined the allosteric influence of native peptides derived from the C-terminus of the Gα subunit (G-peptides) on signaling from two Gi-coupled receptors, adenosine A1 receptor (A1 R) and cannabinoid receptor 1 (CB1 ). We expressed A1 R and CB1 fusions with G-peptides derived from Gαs, Gαi, and Gαq in HEK 293 cells using systematic protein affinity strength modulation (SPASM) and monitored the impact on downstream signaling in the cell compared to a construct lacking G-peptides. We used agonists N6 -Cyclopentyladenosine (CPA) and 5'-N-Ethylcarboxamidoadenosine (NECA) for A1 R and 2-Arachidonoylglycerol (2-AG) and WIN 55,212-2 mesylate (WN) for CB1 . G-peptides derived from Gαi and Gαq enhance agonist-dependent cAMP inhibition, demonstrating their effect as positive allosteric modulators of Gi-coupled signaling. In contrast, both G-peptides suppress agonist-dependent IP1 levels suggesting that they differentially function as negative allosteric modulators of Gq-coupled signaling. Taken together with our previous studies on Gs-coupled receptors, this study provides an extended model for the allosteric effects of G-peptides on GPCR signaling, and highlights their potential as probe molecules to enhance receptor specificity | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a CB1 | |
650 | 4 | |a GTP-binding proteins | |
650 | 4 | |a N(6)-cyclopentyladenosine | |
650 | 4 | |a SCH 442 416 | |
650 | 4 | |a adenosine A1 | |
650 | 4 | |a adenosine-5’-(N-ethylcarboxamide) | |
650 | 4 | |a cannabinoid | |
650 | 4 | |a receptor | |
650 | 4 | |a signal transduction | |
650 | 7 | |a Chromogranins |2 NLM | |
650 | 7 | |a GINIP protein, rat |2 NLM | |
650 | 7 | |a Intracellular Signaling Peptides and Proteins |2 NLM | |
650 | 7 | |a Peptide Fragments |2 NLM | |
650 | 7 | |a Receptor, Adenosine A1 |2 NLM | |
650 | 7 | |a Receptor, Cannabinoid, CB1 |2 NLM | |
650 | 7 | |a Gnas protein, mouse |2 NLM | |
650 | 7 | |a EC 3.6.1.- |2 NLM | |
650 | 7 | |a GTP-Binding Protein alpha Subunits, Gq-G11 |2 NLM | |
650 | 7 | |a EC 3.6.5.1 |2 NLM | |
650 | 7 | |a GTP-Binding Protein alpha Subunits, Gs |2 NLM | |
650 | 7 | |a EC 3.6.5.1 |2 NLM | |
700 | 1 | |a Malik, Rabia U |e verfasserin |4 aut | |
700 | 1 | |a Gupte, Tejas |e verfasserin |4 aut | |
700 | 1 | |a Sivaramakrishnan, Sivaraj |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacology research & perspectives |d 2013 |g 8(2020), 6 vom: 06. Dez., Seite e00673 |w (DE-627)NLM236897691 |x 2052-1707 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2020 |g number:6 |g day:06 |g month:12 |g pages:e00673 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/prp2.673 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2020 |e 6 |b 06 |c 12 |h e00673 |